Hexamethonium (Bromide)
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Hexamethonium (Bromide)
Description :
Hexamethonium Bromide is a non-selective ganglionic nicotinic-receptor antagonist (nAChR) antagonist, with mixed competitive and noncompetitive activity. Hexamethonium Bromide has anti-hypertensive activity. Hexamethonium Bromide attenuates sympathetic activity and blood pressure in spontaneously hypertensive animal models[1][2][3][4].UNSPSC :
12352211Hazard Statement :
H302, H315, H319, H335Target :
Apoptosis; nAChRType :
Reference compoundRelated Pathways :
Apoptosis; Membrane Transporter/Ion Channel; Neuronal SignalingApplications :
Neuroscience-NeurodegenerationField of Research :
Neurological Disease; Cardiovascular DiseaseAssay Protocol :
https://www.medchemexpress.com/hexamethonium-bromide.htmlPurity :
99.91Solubility :
DMSO : 16.67 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mLSmiles :
C[N+](C)(C)CCCCCC[N+](C)(C)C.[Br-].[Br-]Molecular Formula :
C12H30Br2N2Molecular Weight :
362.19Precautions :
H302, H315, H319, H335References & Citations :
[1]Damian J. Williams, et al. Mechanisms involved in nicotinic acetylcholine receptor-induced neurotransmitter release from sympathetic nerve terminals in the mouse vas deferens. PLoS One. 2011; 6 (12) : e29209.|[2]Roger L. Papke, et al. Activation and Inhibition of Mouse Muscle and Neuronal Nicotinic Acetylcholine Receptors Expressed in Xenopus Oocytes. J Pharmacol Exp Ther. 2010 May; 333 (2) : 501–518.|[3]Brian T Hawkins, et al. Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. Am J Physiol Heart Circ Physiol. 2005 Jul;289 (1) :H212-9.|[4]Peng Li, et al. Hexamethonium attenuates sympathetic activity and blood pressure in spontaneously hypertensive rats. Mol Med Rep. 2015 Nov;12 (5) :7116-22.Shipping Conditions :
Room TemperatureStorage Conditions :
4°C (Powder, sealed storage, away from moisture)Scientific Category :
Reference compound1Clinical Information :
No Development ReportedCAS Number :
[55-97-0]

